Prahlad Singh
AMPHENOL CORP /DE/About Prahlad Singh
Prahlad Singh, PhD (age 60), has served as an independent director of Amphenol since 2023. He is President and CEO of Revvity, Inc. (formerly affiliated with PerkinElmer) and holds a BS from Wilson College (Mumbai), a PhD in chemistry from University of Missouri–Columbia, and an MBA from Northeastern University; his research has resulted in several patents and peer‑reviewed publications . He is classified as independent under NYSE standards; all nominees, except the CEO, are deemed independent .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| GE Healthcare | General Manager; prior senior exec roles in strategy, BD, M&A | Not disclosed | Global operating leadership |
| Philips Healthcare | Senior executive roles in strategy, BD, M&A | Not disclosed | Transactions and growth execution |
| DuPont Pharmaceuticals | Leadership roles | Not disclosed | Regional management (APAC, Middle East) |
| Bristol‑Myers Squibb Medical Imaging | Leadership roles; managed APAC/Middle East | Not disclosed | International expansion |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Revvity, Inc. | President & CEO; Director | CEO since Dec 30, 2019; director since Aug 2019 | Public company leader; capital markets, M&A experience |
| Analytical, Life Science & Diagnostics Association | Board member | Not disclosed | Industry association governance |
Board Governance
- Committee memberships: Compensation Committee member; Finance Committee member; Nominating/Corporate Governance Committee member (not a chair) .
- Independence: Board determined Singh is independent (all directors except CEO are independent) .
- Attendance: 100% attendance at Board and Committee meetings in 2024; Board met nine times; relevant committees met 6 (Audit), 4 (Compensation), 2 (NCGC), and 2 (Finance) times .
- Lead Independent Director: Presiding Director David P. Falck can call/lead executive sessions; independent directors meet at least quarterly .
Fixed Compensation
| Component | 2024 Amount (USD) | Notes |
|---|---|---|
| Annual retainer (cash) | $100,000 | Non‑employee director retainer |
| Committee chair fees | $0 | Singh is not a chair |
| Presiding/Chairman fees | $0 | Applies to Presiding Director/Chairman only |
| Total cash | $100,000 | |
| 2025 changes (effective Jan 1, 2025) | Retainer: $115,000; Audit Chair: $30,000; other Chairs: $20,000; Presiding: $45,000; Chairman: $210,000; equity grant value ~ $205,000 | Structure updated; Singh remains member, not chair |
Performance Compensation
| Grant Type | Grant Date | Shares | Grant‑date Fair Value (USD) | Vesting |
|---|---|---|---|---|
| Restricted Stock (Directors Plan) | May 17, 2024 | 2,730 | $180,071 | Fully vests May 14, 2025 (unless meeting date changes) |
- Director equity is time‑based restricted stock; no performance metrics are applied to director compensation awards .
Other Directorships & Interlocks
| Company | Role | Interlock/Transaction Exposure |
|---|---|---|
| Revvity, Inc. | Director; President & CEO | No related‑party transactions disclosed between Amphenol and entities tied to Singh; company policy requires Audit Committee review of related party dealings; 2024 report lists Fidelity plan services only . |
Expertise & Qualifications
- Skills matrix highlights business development and strategy, capital markets, international, manufacturing, M&A, risk oversight, supply chain, talent development, technology .
- Scientific rigor (PhD chemistry) and proven operating/transactional experience at global healthcare and diagnostics companies .
Equity Ownership
| Holder | Shares Beneficially Owned | Direct Shares | Restricted Shares (unvested) | % of Outstanding |
|---|---|---|---|---|
| Prahlad Singh | 9,016 | 6,286 | 2,730 | 0.0007% (9,016 / 1,211,783,313) |
| Notes | Shares outstanding at record date: 1,211,783,313 |
- Stock ownership guidelines: non‑employee directors encouraged to own ≥5x annual cash retainer; compliance status for individual directors is not disclosed .
- Hedging/short sales/derivatives/pledging are prohibited for directors under Insider Trading Compliance Policy .
Governance Assessment
-
Strengths
- Independent, high engagement (100% attendance) and broad committee exposure (Compensation, Finance, NCGC) support board effectiveness .
- Direct equity grant plus ownership guidelines align director incentives with shareholders; hedging/pledging banned, reducing misalignment risk .
- No related‑party transactions identified; Audit Committee must review any such dealings, mitigating conflict risk .
- Board maintains robust governance (proxy access, annual elections, clawback for executives, executive sessions led by Presiding Director) enhancing investor confidence .
-
Watch items
- Singh is the sitting CEO of Revvity (public company), which increases time commitments; current 100% attendance mitigates concern, but ongoing monitoring of engagement is prudent .
- Director ownership is modest in absolute terms relative to APH’s large share count; adherence to 5x retainer guideline over time is important, though individual compliance status is not disclosed .
-
Compensation structure observations (directors)
- Mix is cash retainer plus time‑vested restricted stock; no options or performance‑linked equity for directors, consistent with governance best practice to preserve independence .
- 2025 increases in retainer and equity grant (~$205k) remain benchmarked by an independent consultant (Meridian), signaling market‑aligned board pay without apparent inflationary ratcheting .
-
Board process/ESG oversight
- Clear committee charters; Compensation Committee (includes Singh) oversees “Social” ESG and board compensation; NCGC oversees “Governance”; Audit oversees “Environmental” ESG and cybersecurity/climate‑related risk .
Insider Trades
| Item | Disclosure |
|---|---|
| Form 4 transactions | No Singh‑specific insider transactions are summarized in the 2025 DEF 14A; Related party transactions section lists none beyond plan asset management fees (Fidelity) . |
Overall read‑through: Singh’s independence, full attendance, and service across three key committees (Compensation, Finance, NCGC) are positive signals for governance effectiveness. Absence of related‑party exposure and strict anti‑hedging/pledging policies support alignment; continuing visibility into director stock ownership guideline progress and time commitment (given Revvity CEO role) are the relevant monitoring points for investors .